Discovery of dengue virus NS4B inhibitors

Journal of Virology

Volumn 89, Issue 16, 2015, Pages 8233-8244

  Wang, Qing Yin ^a   Dong, Hongping ^a   Zou, Bin ^a   Karuna, Ratna ^a   Wan, Kah Fei ^a   Zou, Jing ^a   Susila, Agatha ^a   Yip, Andy ^a   Shan, Chao ^a   Yeo, Kim Long ^a   Xu, Haoying ^a   Ding, Mei ^a   Chan, Wai Ling ^a   Gu, Feng ^a   Seah, Peck Gee ^a   Liu, Wei ^a   Lakshminarayana, Suresh B ^a   Kang, CongBao ^b   Lescar, Julien ^c   Blasco, Francesca ^a   Smith, Paul W ^a   Shi, Pei Yong ^a   more..

^a NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^b Agency for Science   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NONSTRUCTURAL PROTEIN 4B; SPIROPYRAZOLOPYRIDONE DERIVATIVE; UNCLASSIFIED DRUG; NS4B PROTEIN, FLAVIVIRUS; SPIRO COMPOUND; SPIROQUINAZOLINE; VIRAL PROTEIN;

AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS INFECTION; DRUG IDENTIFICATION; DRUG SAFETY; DRUG SCREENING; DRUG TARGETING; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MEDICINAL CHEMISTRY; MOUSE; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RAT; REPLICON; RNA VIRUS INFECTION; TREATMENT RESPONSE; VIREMIA; VIRUS INHIBITION; VIRUS MUTATION; VIRUS RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CHEMISTRY; DRUG DEVELOPMENT; DRUG EFFECTS; HAMSTER;

DENGUE VIRUS; MUS;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CRICETINAE; DENGUE VIRUS; DRUG DISCOVERY; HUMANS; SPIRO COMPOUNDS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84938152526     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00855-15     Document Type: Article

References (34)

1. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes CL, Drake JM, Brownstein JS, Hoen AG, Sankoh O, Myers MF, George DB, Jaenisch T, Wint GR, Simmons CP, Scott TW, Farrar JJ, Hay SI. 2013. The global distribution and burden of dengue. Nature 496:504-507. http://dx.doi.org/10.1038/nature12060.
2. Fink K, Shi PY. 2014. Live attenuated vaccine: the first clinically approved dengue vaccine? Expert Rev Vaccines 13:185-188. http://dx.doi.org/10.1586/14760584.2014.870888.
3. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, Suvannadabba S, Jiwariyavej V, Dulyachai W, Pengsaa K, Wartel TA, Moureau A, Saville M, Bouckenooghe A, Viviani S, Tornieporth NG, Lang J. 2012. Protective efficacy of the recombinant, liveattenuated, CYDtetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380:1559-1567. http://dx.doi.org/10.1016/S0140-6736(12)61428-7.
4. Capeding MR, Tran NH, Hadinegoro SR, Ismail HI, Chotpitayasunondh T, Chua MN, Luong CQ, Rusmil K, Wirawan DN, Nallusamy R, Pitisuttithum P, Thisyakorn U, Yoon IK, van der Vliet D, Langevin E, Laot T, Hutagalung Y, Frago C, Boaz M, Wartel TA, Tornieporth NG, Saville M, Bouckenooghe A, CYD14 Study Group. 2014. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 384:1358-1365. http://dx.doi.org/10.1016/S0140-6736(14)61060-6.
5. Villar L, Dayan GH, Arredondo-Garcia JL, Rivera DM, Cunha R, Deseda C, Reynales H, Costa MS, Morales-Ramirez JO, Carrasquilla G, Rey LC, Dietze R, Luz K, Rivas E, Miranda Montoya MC, Cortes Supelano M, Zambrano B, Langevin E, Boaz M, Tornieporth N, Saville M, Noriega F, CYD15 Study Group. 2015. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 372:113-123. http://dx.doi.org/10.1056/NEJMoa1411037.
6. Nguyen NM, Tran CN, Phung LK, Duong KT, Huynh HA, Farrar J, Nguyen QT, Tran HT, Nguyen CV, Merson L, Hoang LT, Hibberd ML, Aw PP, Wilm A, Nagarajan N, Nguyen DT, Pham MP, Nguyen TT, Javanbakht H, Klumpp K, Hammond J, Petric R, Wolbers M, Nguyen CT, Simmons CP. 2013. A randomized, double-blind placebo controlled trial of balapiravir, a polymerase inhibitor, in adult dengue patients. J Infect Dis 207:1442-1450. http://dx.doi.org/10.1093/infdis/jis470.
7. Low JG, Sung C, Wijaya L, Wei Y, Rathore AP, Watanabe S, Tan BH, Toh L, Chua LT, Hou Y, Chow A, Howe S, Chan WK, Tan KH, Chung JS, Cherng BP, Lye DC, Tambayah PA, Ng LC, Connolly J, Hibberd ML, Leo YS, Cheung YB, Ooi EE, Vasudevan SG. 2014. Efficacy and safety of celgosivir in patients with dengue fever (CELADEN): a phase 1b, randomised, double-blind, placebo-controlled, proof-of-concept trial. Lancet Infect Dis 14:706-715. http://dx.doi.org/10.1016/S1473-3099(14)70730-3.
8. Tricou V, Minh NN, Van TP, Lee SJ, Farrar J, Wills B, Tran HT, Simmons CP. 2010. A randomized controlled trial of chloroquine for the treatment of dengue in Vietnamese adults. PLoS Negl Trop Dis 4:e785. http://dx.doi.org/10.1371/journal.pntd.0000785.
9. Tam DT, Ngoc TV, Tien NT, Kieu NT, Thuy TT, Thanh LT, Tam CT, Truong NT, Dung NT, Qui PT, Hien TT, Farrar JJ, Simmons CP, Wolbers M, Wills BA. 2012. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 55:1216-1224. http://dx.doi.org/10.1093/cid/cis655.
10. Lim SP, Wang QY, Noble CG, Chen YL, Dong H, Zou B, Yokokawa F, Nilar S, Smith P, Beer D, Lescar J, Shi PY. 2013. Ten years of dengue drug discovery: progress and prospects. Antiviral Res 100:500-519. http://dx.doi.org/10.1016/j.antiviral.2013.09.013.
11. Ng CY, Gu F, Phong WY, Chen YL, Lim SP, Davidson A, Vasudevan SG. 2007. Construction and characterization of a stable subgenomic dengue virus type 2 replicon system for antiviral compound and siRNA testing. Antiviral Res 76:222-231. http://dx.doi.org/10.1016/j.antiviral.2007.06.007.
12. Yin Z, Chen YL, Schul W, Wang QY, Gu F, Duraiswamy J, Kondreddi RR, Niyomrattanakit P, Lakshminarayana SB, Goh A, Xu HY, Liu W, Liu B, Lim JY, Ng CY, Qing M, Lim CC, Yip A, Wang G, Chan WL, Tan HP, Lin K, Zhang B, Zou G, Bernard KA, Garrett C, Beltz K, Dong M, Weaver M, He H, Pichota A, Dartois V, Keller TH, Shi PY. 2009. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci U S A 106:20435-20439. http://dx.doi.org/10.1073/pnas.0907010106.
13. Qing M, Zou G, Wang QY, Xu HY, Dong H, Yuan Z, Shi PY. 2010. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob Agents Chemother 54:3686-3695. http://dx.doi.org/10.1128/AAC.00561-10.
14. Zou G, Chen YL, Dong H, Lim CC, Yap LJ, Yau YH, Shochat SG, Lescar J, Shi PY. 2011. Functional analysis of two cavities in flavivirus NS5 polymerase. J Biol Chem 286:14362-14372. http://dx.doi.org/10.1074/jbc.M110.214189.
15. Shi PY, Tilgner M, Lo MK, Kent KA, Bernard KA. 2002. Infectious cDNA clone of the epidemic West Nile virus from New York City. J Virol 76:5847-5856. http://dx.doi.org/10.1128/JVI.76.12.5847-5856.2002.
16. Zou G, Xu HY, Qing M, Wang QY, Shi PY. 2011. Development and characterization of a stable luciferase dengue virus for high-throughput screening. Antiviral Res 91:11-19. http://dx.doi.org/10.1016/j.antiviral.2011.05.001.
17. Puig-Basagoiti F, Tilgner M, Forshey BM, Philpott SM, Espina NG, Wentworth DE, Goebel SJ, Masters PS, Falgout B, Ren P, Ferguson DM, Shi PY. 2006. Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother 50:1320-1329. http://dx.doi.org/10.1128/AAC.50.4.1320-1329.2006.
18. Zou J, Xie X, Lee LT, Chandrasekaran TR, Reynaud A, Yap L, Wang QY, Dong H, Kang C, Yuan Z, Lescar J, Shi PY. 2014. Dimerization of flavivirus NS4B protein. J Virol 88:3379-3391. http://dx.doi.org/10.1128/JVI.02782-13.
19. Zou B, Chan WL, Ding M, Leong SY, Nilar S, Seah PG, Liu W, Karuna R, Blasco F, Yip A, Chao A, Susila A, Dong H, Wang QY, Xu HY, Chan K, Wan KF, Gu F, Diagana TT, Wagner T, Dix I, Shi P-Y, Smith PW. 2015. Lead optimization of spiropyrazolopyridones: a new and potent class of dengue virus inhibitors. ACS Med Chem Lett 6:344-348. http://dx.doi.org/10.1021/ml500521r.
20. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG. 2007. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 195:665-674. http://dx.doi.org/10.1086/511310.
21. Noble CG, Chen YL, Dong H, Gu F, Lim SP, Schul W, Wang QY, Shi PY. 2010. Strategies for development of dengue virus inhibitors. Antiviral Res 85:450-462. http://dx.doi.org/10.1016/j.antiviral.2009.12.011.
22. Miller S, Sparacio S, Bartenschlager R. 2006. Subcellular localization and membrane topology of the dengue virus type 2 non-structural protein 4B. J Biol Chem 281:8854-8863. http://dx.doi.org/10.1074/jbc.M512697200.
23. Xie X, Wang QY, Xu HY, Qing M, Kramer L, Yuan Z, Shi PY. 2011. Inhibition of dengue virus by targeting viral NS4B protein. J Virol 85: 11183-11195. http://dx.doi.org/10.1128/JVI.05468-11.
24. Youn S, Li T, McCune BT, Edeling MA, Fremont DH, Cristea IM, Diamond MS. 2012. Evidence for a genetic and physical interaction between nonstructural proteins NS1 and NS4B that modulates replication of West Nile virus. J Virol 86:7360-7371. http://dx.doi.org/10.1128/JVI.00157-12.
25. Umareddy I, Chao A, Sampath A, Gu F, Vasudevan SG. 2006. Dengue virus NS4B interacts with NS3 and dissociates it from singlestranded RNA. J Gen Virol 87:2605-2614. http://dx.doi.org/10.1099/vir.0.81844-0.
26. Zou J, Lee LT, Wang QY, Xie XP, Lu SY, Yau YH, Yuan ZM, Shochat SG, Kang CB, Lescar J, Shi PY. 2015. Mapping the interactions between the NS4B and NS3 proteins of dengue virus. J Virol 89:3471-3483. http://dx.doi.org/10.1128/JVI.03454-14.
27. Zou J, Xie X, Wang QY, Dong H, Lee MY, Kang C, Yuan Z, Shi PY. 2015. Characterization of dengue virus NS4A and NS4B protein interaction. J Virol 89:3455-3470. http://dx.doi.org/10.1128/JVI.03453-14.
28. Patkar CG, Larsen M, Owston M, Smith JL, Kuhn RJ. 2009. Identification of inhibitors of yellow fever virus replication using a replicon-based high-throughput assay. Antimicrob Agents Chemother 53:4103-4114. http://dx.doi.org/10.1128/AAC.00074-09.
29. van Cleef KW, Overheul GJ, Thomassen MC, Kaptein SJ, Davidson AD, Jacobs M, Neyts J, van Kuppeveld FJ, van Rij RP. 2013. Identification of a new dengue virus inhibitor that targets the viral NS4B protein and restricts genomic RNA replication. Antiviral Res 99:165-171. http://dx.doi.org/10.1016/j.antiviral.2013.05.011.
30. Xie X, Zou J, Wang QY, Shi PY. 2015. Targeting dengue virus NS4B protein for drug discovery. Antiviral Res 118:39-45. http://dx.doi.org/10.1016/j.antiviral.2015.03.007.
31. Green S, Rothman A. 2006. Immunopathological mechanisms in dengue and dengue hemorrhagic fever. Curr Opin Infect Dis 19:429-436. http://dx.doi.org/10.1097/01.qco.0000244047.31135.fa.
32. Sofia MJ. 2014. Beyond sofosbuvir: what opportunity exists for a better nucleoside/nucleotide to treat hepatitis C? Antiviral Res 107:119-124. http://dx.doi.org/10.1016/j.antiviral.2014.04.008.
33. Chen YL, Abdul Ghafar N, Karuna R, Fu Y, Lim SP, Schul W, Gu F, Herve M, Yokohama F, Wang G, Cerny D, Fink K, Blasco F, Shi PY. 2014. Activation of peripheral blood mononuclear cells by dengue virus infection depotentiates balapiravir. J Virol 88:1740-1747. http://dx.doi.org/10.1128/JVI.02841-13.
34. Blight KJ, Kolykhalov AA, Rice CM. 2000. Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974. http://dx.doi.org/10.1126/science.290.5498.1972.